Cost-utility analysis of Lenvatinib vs. Sorafenib in Unresectable hepatocellular carcinoma in Iran
{{output}}
Background: Hepatocellular carcinoma (HCC) is a global health issue and the third leading cause of cancer-related deaths. For patients with unresectable HCC (uHCC), Sorafenib and Lenvatinib, are key treatments. This study evaluat... ...
